A Scandinavian controlled, randomized, open-label, and multi-centre study evaluating if once-daily tacrolimus or twice-daily cyclosporin, reduces the 3-year incidence of chronic lung allograft dysfunction after lung transplantation

Trial Profile

A Scandinavian controlled, randomized, open-label, and multi-centre study evaluating if once-daily tacrolimus or twice-daily cyclosporin, reduces the 3-year incidence of chronic lung allograft dysfunction after lung transplantation

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Dec 2017

At a glance

  • Drugs Tacrolimus (Primary) ; Ciclosporin
  • Indications Lung transplant rejection
  • Focus Therapeutic Use
  • Acronyms ScanCLAD
  • Most Recent Events

    • 24 Oct 2016 Status changed from not yet recruiting to recruiting.
    • 17 Oct 2016 Status changed from recruiting to not yet recruiting.
    • 07 Jun 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top